Regulatory Systems in Bone Marrow for Hematopoietic Stem/Progenitor Cells Mobilization and Homing

P. Alvarez,1,2 E. Carrillo,1,2 C. Vélez,1,2 F. Hita-Contreras,1,3 A. Martínez-Amat,1,3 F. Rodríguez-Serrano,1,2 H. Boulaiz,1,2 R. Ortiz,1,3 C. Melguizo,1,2 J. Prados,1,2 and A. Aránega1,2

1 Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18100 Granada, Spain
2 Department of Human Anatomy and Embryology, School of Medicine, University of Granada, 18071 Granada, Spain
3 Department of Health Science, University of Jaén, 23071 Jaén, Spain

Correspondence should be addressed to E. Carrillo; esmeral@ugr.es

Received 4 March 2013; Revised 22 April 2013; Accepted 24 May 2013

Academic Editor: Robert Möhle

Copyright © 2013 P. Alvarez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Regulation of hematopoietic stem cell release, migration, and homing from the bone marrow (BM) and of the mobilization pathway involves a complex interaction among adhesion molecules, cytokines, proteolytic enzymes, stromal cells, and hematopoietic cells. The identification of new mechanisms that regulate the trafficking of hematopoietic stem/progenitor cells (HSPCs) cells has important implications, not only for hematopoietic transplantation but also for cell therapies in regenerative medicine for patients with acute myocardial infarction, spinal cord injury, and stroke, among others. This paper reviews the regulation mechanisms underlying the homing and mobilization of BM hematopoietic stem/progenitor cells, investigating the following issues: (a) the role of different factors, such as stromal cell derived factor-1 (SDF-1), granulocyte colony-stimulating factor (G-CSF), and vascular cell adhesion molecule-1 (VCAM-1), among other ligands; (b) the stem cell count in peripheral blood and BM and influential factors; (c) the therapeutic utilization of this phenomenon in lesions in different tissues, examining the agents involved in HSPCs mobilization, such as the different forms of G-CSF, plerixafor, and natalizumab; and (d) the effects of this mobilization on BM-derived stem/progenitor cells in clinical trials of patients with different diseases.

1. Introduction

For many decades, bone marrow (BM) transplantation was the only viable method for transplanting hematopoietic stem cells, although their presence had been demonstrated in peripheral blood. Peripheral blood was not used for two main reasons: the number of circulating stem cells that could be gathered by available methods was thought to be inadequate for their autologous and allogeneic transplantation; and the number of contaminated T cells was considered too high for safe allogeneic transplantation [1].

Under steady-state conditions, a small amount of hematopoietic stem cells constantly leave the BM and penetrate tissues, returning to the BM or peripheral niches via the blood or lymphatic system [2]. A niche is a subgroup of tissue cells and extracellular substrates that can indefinitely harbor one or more stem cells and control their self-renewal and progeny in vivo [3]. The BM niche is strategically placed and organized to support the continuous and balanced production of hematopoietic cells through the strict control of cell survival, self-renewal, and differentiation [4].

The successful transplantation of hematopoietic stem/progenitor cells (HSPCs) is based on their ability to home to the BM niche and on their engraftment capacity. Interactions between HSPCs and their niches are altered during mobilization and must be reestablished during BM homing and repopulation. The homing of HSPCs to BM is a rapid process that takes place during the hours after transplantation and is an essential and necessary requirement for repopulation and engraftment [5].

The use of mobilized peripheral blood is now the method of choice in autologous transplantation for various reasons,
including an elevated production of immature cells, and, in comparison to the utilization of BM, the shorter time period required for a satisfactory repopulation, the more rapid engraftment, fewer technical difficulties, lower risk, and considerably less pain [6].

HSPCs were used later in allogeneic transplantation [7]. Although BM and peripheral blood are both still considered a source of stem/progenitor cells for this purpose [8, 9], peripheral blood is used in 71% of allogeneic transplantations [6].

Therefore, the regulation of HSPC release from BM and their migration and homing and the mechanism of mobilization pathways involve a complex interaction among adhesion molecules, cytokines, proteolytic enzymes, stromal cells, and HSPCs [10]. The identification of new mechanisms that regulate stem cell trafficking may have important implications for hematopoietic transplants and for cell therapies in regenerative medicine (e.g., for infarcted heart, injured spinal cord, and stroke) [11].

2. Regulation Mechanisms for the Mobilization and Homing of HSPCs in Bone Marrow

2.1. Factors That Affect Stem Cell Mobilization. Granulocyte colony stimulating factor (G-CSF) is the most widely used agent for stem cell mobilization due to its power and lack of severe toxicity. It has two stem cell mobilization mechanisms: firstly, interruption of the anchoring mechanism through downregulation of the expression of stromal cell derived factor-1 (SDF-1) and activation of the CD26 protease that cleaves the SDF-1 N-terminal, impeding binding to CXCR4 by decreasing the function of integrin-β1; and secondly, an increase in serum levels of additional cytokines and growth factors [12–14].

Studies of G-CSF in animals with tissue ischemia have demonstrated therapeutic benefits, although with the drawback of a possibly favoring of atherosclerosis [15, 16]. After myocardial infarction (MI), G-CSF promotes the mobilization of cardiac tissue HSPCs and improves the regeneration of cardiomyocytes and blood vessels by the mobilization and subsequent transdifferentiation of BM stem cells. It has been verified that G-CSF avoids H₂O₂-induced apoptosis of cardiomyocytes and facilitates cardiac remodeling after MI [17].

However, different studies have demonstrated that the utilization of G-CSF has various disadvantages, including a low therapeutic response and the need for multiple daily injections over several days. These drawbacks can be overcome by combining G-CSF with other cytokines and using different growth factor mobilization strategies [18–20].

Chemokine CXCL12, also known as SDF-1α, was identified in the supernatant of BM stromal cells; it is expressed at high levels in BM and produced by osteoblasts, endothelial cells, and reticular cells dispersed throughout the BM stroma. It is a potent chemoattractant for HSPCs and has been demonstrated to regulate cell adhesion and survival and cell cycle status [21]. Méndez-Ferrer et al. [22] studied CXCL12 levels in BM, observing that their production follows a circadian rhythm, regulated by the sympathetic nervous system, with noradrenaline acting via β2 adrenoreceptors on osteoblasts and via β3 adrenoreceptors on nestin-positive stem cells to reduce their production of CXCL12.

Receptors. Two chemokine receptors for CXCL12 have been identified (CXCR4 and CXCR7). The presence of CXCR4 on the cell surface bound to other factors promotes migration and homing into or from the BM niche [23, 24]. CXCR4 couples to a series of signaling molecules, stimulating leukocyte chemotaxis and stem cells that express the receptor [11, 25]. The interaction of CXCL12 with CXCR4 in HSPCs is considered an essential signal for regulating HSPC trafficking in BM. Cells without surface expression of CXCR4 are not sensitive to mobilization using CXCR4 receptor agonists or antagonists. One of them, AMD3100, a bicyclam CXCR4 antagonist that is strongly synergic with G-CSF in humans, increases mobilization by one to two logs over G-CSF alone [26, 27]. It is expressed in most types of cancer, including breast cancer, prostate cancer, and kidney clear cell carcinoma [28].

CXCR7 has been identified as a second high-affinity receptor for CXCL12 but does not couple to signaling pathways for migration. It regulates the transendothelial migration of CXCR4+CXCR7+ tumor cells towards a CXCL12 source, an effect that can be blocked by CXCR7-specific antagonists [29]. Upon binding to CXCR7, chemokine CXCL12 is internalized and subsequently degraded; therefore, CXCR7 appears to act as a CXCL12 sink [12]. The two receptors (CXCR4 and CXCR7) interact and can even form functional heterodimers. CXCR4 inhibition does not appear to affect CXCR7 function. Thus, specific blockade of CXCR4 with AMD3100/plerixafor may increase the functions of CXCR7 mediated by SDF-1 [29, 30]. CXCR7 is expressed in cancers of breast, brain, liver, pancreas, lung, and prostate, melanomas, and rhabdomyosarcomas [31, 32].

2.2. Mobilization and Homing of Hematopoietic Stem Cells in Bone Marrow and Different Ligands

2.2.1. SDF-1/CXCR4 Axis in Mobilization and Homing. SDF-1 is essential for the circulation, homing, and retention of HSPCs in BM. In 2005, Lapidot et al. demonstrated that SDF-1 is expressed by immature human osteoblasts in the endosteal region [5]. The interaction between SDF-1 and its CXCR4 receptor has been described as a major axis for regulating the migration and mobilization of HSPCs under steady-state conditions [33, 34].

Mobilized human progenitor cells express CD34+ and reduced CXCR4 levels, which correlate with greater mobilization, suggesting the participation of SDF-1/CXCR4 interactions in this process. Overexpression of SDF-1 was found to induce the mobilization of stem cells in murine blood [35].

New evidence shows that, in addition to SDF-1, the migration of HSPCs is directed by gradients of the bioactive lipids sphingosine-1 phosphate (S1P) and ceramide-1 phosphate (C1P), which are products of membrane lipid metabolism.
and involved in stem cell trafficking. This mechanism is based on the significant increase produced by molecules in the chemotactic responsiveness of HSPCs to very low SDF-1 gradients. At molecular level, this sensitization of the responsiveness to SDF-1 depends on the incorporation of the CXCR4 receptor into membrane lipid rafts, activating the complement cascade (CC) [36, 37].

The importance of the CC in HSPC homing has been demonstrated in complement component-deficient mice. Specifically, mice that are deficient in C3 and C5 engraft less successfully with HSPCs from wild-type animals, while HSPCs from C3a receptor-deficient mice show defective engraftment in wild-type littermates. Hence, activation of the CC in BM induces a highly proteolytic microenvironment that degrades SDF-1 [38].

It has been reported that hyaluronic acid (HA) and thrombin (TH) can increase the response of peripheral HSPCs to an SDF-1 gradient. This action may be related to membrane type-1 matrix metalloproteinase (MT1-MMP), increasing its expression and favoring the passage of the HSPCs towards a low SDF-1 gradient [34, 39]. The priming/trIGGERing effect produced by supernatants of leukapheresis products or their components (fibronectin, fibronectin, complement C3a, platelet-derived microvesicles [PMV], HA, thrombin) was found to be related to an increased secretion of MMP-2 and MMP-9, which, together with the SDF-1-CXCR4 axis, favor the homing of these cells [40] (Figure 1).

2.2.2. Role of G-CSF in the Mobilization and Homing of HSPCs in BM. G-CSF induces the mobilization of HSPCs through the proteolytic inactivation of both CXCL12 and CXCR4 by the granulocyte proteases neutrophil elastase (NE) and cathepsin (CG), which are released in large amounts in proteolytically active form in the BM stroma during G-CSF-induced mobilization. After G-CSF administration, neutrophils show increases in their expression of FcgRI/CD64, CD11b, and FcgRIII/CD16 and in their release of elastase and lactoferrin, allowing neutrophil progenitors to be activated and degranulated directly in the BM stroma during mobilization before their migration into peripheral blood. After their release into the BM environment, these proteases may inactivate a number of proteins essential for retaining HSPCs within the BM, that is, vascular cell adhesion molecule-1 (VCAM-1)-integrin, chemokine CXCL12/SDF-1 and its CXCR4 receptor (in humans), and c-Kit receptor, all of which may trigger HSPC mobilization [41, 42].

Plasminogen (Plg) is a glycoprotein present in blood plasma and in most extracellular fluids as the inactive precursor of a protease enzyme (plasmin) responsible for the dissolution of clots after thrombosis [43]. Various authors have confirmed that Plg plays an essential role in the mobilization of BM stem cells to the peripheral circulation, particularly in G-CSF-induced mobilization of HPSCs. Plg binds to the BM extracellular matrix (ECM) and, after conversion into plasmin, it degrades various proteins of the ECM, including fibrin, laminin, and plasmin. Plg can also activate other proteases, such as MMP-3, MMP-9, MMP-12, and MMP-13, to degrade other matrix components, including collagen [44].

There have also been reports on the importance of urokinase Plg activator (uPA), part of the plasminogen activating system, in the activity of α1β4 integrin in BM homing. Intact uPA receptors (uPARs) are required for the adhesion and engraftment of HSPCs to BM [45].

2.2.3. Other Ligands. The adhesion molecule Very Late Antigen (VLA)-4 (α4β1-integrin) is expressed on murine HSPCs and on human CD34+ early hematological progenitor cells [46]. Blocking the interaction between VLA-4 and its ligands expressed on BM stroma, by using specific antibodies or small molecule inhibitors, induces rapid mobilization of HSPCs in humans, primates, and mice [47, 48].

One example is the interaction between VLA-4 and VCAM-1 on BM stromal cells, which is essential for BM homing during development and posttransplantation. HSPCs were found to be mobilized by inhibition of this interaction through the administration of function-blocking anti-VLA-4 or anti-VCAM-1 mAbs or through the conditional deletion of either α4 integrin or VCAM-1 gene [41].

With regard to the mechanism, VCAM-1 is a substrate for both neutrophil serine-proteases, NE and CG, which accumulate in the BM extracellular fluid during mobilization and cleave VCAM-1 expressed in mouse BM stroma. As a result, the concentrations of soluble VCAM-1 fragments and NE increase in the blood of patients after mobilization. Serine proteases are the sole regulators of VCAM-1 levels in the BM [49].

Tyrosine-kinase c-KIT/CD117 receptor plays an important role in mobilization. G-CSF induces the release in the BM of proteases that remove c-KIT receptor (CD117) from the surface of HSPCs. Administration of soluble KIT, which binds to and blocks the endogenous cell factor KIT ligand, in synergy with G-CSF, increases HSPC mobilization. The serineproteases in G-CSF remove c-KIT in small fragments, and its administration to mice reduces c-KIT expression in primitive hematopoietic cells in the BM and peripheral blood. Proteases able to remove c-KIT include NE, CG, proteinase-3, and MMP-9 [50]. Neutrophils are the main source of these proteases, which provide macrophages with a new pathway for regulating the surface expression of c-KIT on HSPCs and may be in part responsible for the downregulation of c-KIT expression on HSPCs mobilized in vivo. We highlight that removal of the extracellular domain of c-KIT does not activate its kinase domain; therefore, c-KIT removal during mobilization represents a function loss [51, 52].

3. Quantifying HSPCs Mobilization and Homing

Stem cell quantification is usually based on peripheral blood samples, but this method can be challenging. Besides the technical difficulty of precisely determining stem cell mobilization, an increase in stem cells can take place in non-BM tissues, such as splenic or adipose tissue [41].
Various factors can influence the quantification of mobilized stem cells. One example is the daily variations in BM SDF-1α levels, which means that the stem cell count may vary according to the time of day that the sample is drawn [22]. In addition, HSPCs mobilized with CXCL2 are less dependent on CXCR4 in comparison to those mobilized with G-CSF, which are in turn more dependent on selectins and integrins [53]. After mobilization, stem cells may rapidly home back to the BM, but they may also redistribute to other tissues with local stem cell niches, such as the liver, spleen, lungs, myocardium, and adipose tissue [54–57]. Thus, the count of mobilized stem cells in peripheral blood may include not only those from the BM but also those from these other organs.

Recent studies demonstrated that the mobilization of different subpopulations of progenitor cells in the BM can be directly and accurately counted, allowing the effectiveness of different mobilizing agents to be compared over the short and long term [58]. In these experiments, instead of drawing peripheral blood samples, an in situ perfusion system is placed in the hind limb of the mouse, allowing specific counts to be made of the total number of hematopoietic progenitor, endothelial and mesenchymal cells mobilized by the BM during a given time period.

It has been reported that the number of HSPCs is inadequate in around 20% of patients treated with G-CSF for BM transplantation. Successful hematopoietic reconstitution requires the transplant of at least \(2 \times 10^6\) CD34+ cells/kg, and a higher number is associated with a lower incidence of graft-versus-host disease [59, 60].

4. Therapeutic Outcomes: HSPC Mobilization

In the clinical setting, HSPC mobilization from the BM to blood has been used for stem cell transplantation and to stimulate angiogenesis in ischemic tissues [61]. Factors that limit the therapeutic potential of HSPCs include advanced age and cardiovascular risk factors, including hypercholesterolemia, hypertension, and smoking [62].

4.1. Current Standard Agents. Since the early 1990s, G-CSF has been the most widely used agent to mobilize HSPCs for BM transplants [63]. The administration of exogenous G-CSF increases the production of neutrophils by the BM, inducing a rapid exit of HSPCs. Numerous studies have compared the effectiveness of different forms of G-CSF (pegfilgrastim, pegylated form; filgrastim, nonglycosylated form; lenograstim, glycosylated form), which are yet to be well defined, and they found little difference among them [64–66]. Filgrastim (or lenograstim in some countries) remains the agent of choice for the mobilization of allogeneic peripheral blood stem cells from normal donors [67]. The Food and Drug Administration approved pegfilgrastim for reducing the duration and severity of the neutropenia associated with many chemotherapy regimens.

A highly significant positive correlation has been found between the concentration of CD34+ cells before apheresis in peripheral blood and the predicted quality of collections from one-to-three leukaphereses [68–72]. The most frequent G-CSF dose for mobilization in healthy donors is 10 \(\mu g/kg\) day subcutaneously from day 5 until sufficient CD34+ cells are
collected. Various authors found no increase in stem cell yields at higher G-CSF doses [67, 73]. Although CD34+ cell mobilization is increased by its administration twice daily [74], a single dose is preferred [75]. G-CSF is generally well tolerated, and the most commonly observed adverse effects are bone pain, fatigue, nausea, and headache [76, 77]. In a large retrospective study of mobilization in 85 healthy donors, a yield of >85% CD34+ cells was more frequently obtained in the afternoon than in the morning [78]. It should be borne in mind that G-CSF-mobilized HSPCs are different from those present in the BM under normal conditions and express lower levels of c-kit, VLA-4 integrin, and CXCR4 [61].

Most centers use G-CSF alone or in combination with chemotherapy in mobilization regimens [79, 80]. A higher CD34+ cell yield is obtained with G-CSF plus chemotherapy than with G-CSF, besides the antitumor effect [81, 82]. In most patients, the mobilization procedure is started with G-CSF after the 2nd or 3rd cycle of chemotherapy treatment. In patients with multiple myeloma (MM) or non-Hodgkin lymphoma (NHL), cyclophosphamide is followed by the administration of 5 μg/kg G-CSF [83]. Higher doses of chemotherapy have been associated with a greater frequency of platelet transfusion and hospitalization for febrile neutropenia [82].

It has been estimated that the incidence of poor mobilizers ranges from 5% to 40% of healthy donors and patients [71, 84, 102, 103]. G-CSF has been reported to fail to mobilize a sufficient number of PBSCs for transplantation in some elderly patients and especially in patients with a history of chemotherapy or radiotherapy [69, 84, 85, 93, 97, 103]. Other factors associated with poor mobilization include a low platelet count immediately before mobilization [85], baseline thrombocytopenia [85, 92], diabetes [104], and a low TNF-α level [105]. However, it is difficult to predict mobilization in donors due to the absence of well-established predictive factors [68–71, 84–101], and there is no consensus on the definition of poor mobilizers [69]. Table 1 lists variables that have been associated with mobilization failure risk. Olivieri et al. and the “Gruppo Italiano Trapianto di Midollo Osseo” [87] recently attempted to clarify the definition of “poor mobilizers” in lymphomas and multiple myeloma patients. They proposed a peak of CD34+ cells of >20 μL in peripheral blood before collection as a reliable indicator of satisfactory mobilization capacity. Poor mobilization has important consequences, increasing the morbidity after repeated mobilization attempts and significantly reducing the possibility of transplantation [66].

| Variable | Main references |
|----------|-----------------|
| Age | Hosing et al., 2009 [84] |
| | Kuittinen et al., 2004 [85] |
| | Wuchter et al., 2010 [86] |
| | Olivieri et al., 2012 [87] |
| Mobilization with G-CSF alone | Hosing et al., 2009 [84] |
| | Petit et al., 2002 [88] |
| | Bensinger et al., 2009 [89] |
| Bone marrow infiltration by tumor cells | Kuittinen et al., 2004 [85] |
| | Demirer et al., 1996 [90] |
| Disease | Mohty and Ho, 2011 [69] |
| | Gertz et al., 2010 [71] |
| | Jantunen et al., 2008 [92] |
| | Haas et al., 1994 [93] |
| | Wuchter et al., 2010 [86] |
| | Bensinger et al., 2009 [89] |
| | Lysak et al., 2005 [94] |
| | Laszlo et al., 2004 [95] |
| | Popat et al., 2009 [96] |
| Previous myelotoxic chemotherapy | Bensinger et al., 1995 [70] |
| Previous extensive radiotherapy to BM | Haas et al., 1994 [93] |
| | Sevilla et al., 2013 [97] |
| | Demirer et al., 1996 [90] |
| | Olivieri et al., 2012 [87] |
| Low premobilization BM cellularity | Hosing et al., 2009 [84] |
| | Olivieri et al., 2012 [87] |
| Low baseline CD34+ cell count | Fruehauf et al., 1999 [68] |
| | Han et al., 2012 [98] |
| | Fu et al., 2006 [99] |
| Low platelet count before mobilization | Fruehauf et al., 1999 [68] |
| | Hosing et al., 2009 [84] |
| | Wuchter et al., 2010 [86] |
| | Han et al., 2012 [98] |
| | Suzuya et al., 2005 [100] |
| | Zubair et al., 2008 [101] |

4.2. Novel Mobilizing Agents. Plerixafor (AMD3100) has emerged as a promising HSPC mobilization agent. It is a reversible CXCR4 antagonist and produces the fast release of stem cells from BM niches into the blood stream [54, 106]. High expectations have been raised by this agent in the setting of PBSC transplantation [69, 106], because of its ability to mobilize large numbers of CD34+ cells in patients with a poor response to G-CSF administration [54, 107, 108]. The combination of plerixafor with G-CSF produces even greater increases in circulating CD34+ cells [109]. It is also effective in patients that have previously received chemotherapy, and it acts in synergy with G-CSF and chemotherapy [54, 66, 107]. In December 2008, the United States Food and Drug Administration approved plerixafor in combination with G-CSF for HPSC mobilization in patients with NHL and blood stream
undergoing autologous peripheral blood hematopoietic cell transplantation [67].

The recommended standard dose of plerixafor is 0.24 mg/kg/day by subcutaneous injection, with adjustments in particular cases such as myeloma patients with advanced renal failure [110]. Plerixafor used alone rapidly mobilizes HSPCs, reaching a maximum at 6–9 h, and it improves the yield in healthy donors either as a single agent or in combination with G-CSF [30]. Recent research by Abhyankar et al. [111] confirmed that superior results are obtained when plerixafor is given at 5:00 PM the evening before apheresis. The most common adverse effects of plerixafor are mild-moderate gastrointestinal reactions, injection-site reactions, and paresthesias [112].

G-CSF plus plerixafor was more effective for first-line mobilization than G-CSF alone in MM and NHL patients [113] and also proved effective in patients with Hodgkin’s lymphoma (HL) [114, 115]. Various studies found that this combination can safely and effectively remobilize NHL patients in whom previous mobilization approaches have failed [116, 117]. This combination may be of special value in heavily pretreated patients [118].

There is still little experience of mobilization regimens using plerixafor in combination with chemotherapy plus G-CSF [119, 120]. Plerixafor may be useful for HPSC mobilization in patients needing high chemotherapy doses as well as in patients with risk factors for poor mobilization, for example, age, history of radiotherapy or exposure to fludarabine, or lenalidomide, among others [72]. Yannaki et al. [121] proposed G-CSF or plerixafor as mobilizers in nonsplenectomized adult patients with thalassemia and plerixafor in splenectomized thalassemic adults. It has also been suggested that HPSC mobilization would be improved by plerixafor combined with G-CSF and pegylated-G-CSF after chemotherapy in patients with advanced germ cell cancer [122] as well as in those with MM or lymphoma.

For the appropriate use of immediate salvage plerixafor, it is critical to measure real-time indicators of poor and slow mobilizers during mobilization treatments. It is indicated when the concentration of CD34+ cells is <5-6/μL on day 4 of G-CSF apheresis [123]. Awan et al. [124] administered salvage plerixafor in patients failing chemotherapy and G-CSF mobilization and obtained ≥2 × 10^6 CD34+ cells/kg in all cases. Although plerixafor represents an advance in HSPC mobilization, 30% of patients that fail with G-CSF protocols also fail with G-CSF plus plerixafor, which appears to be attributable to a low or defective reserve of HSPCs or niche problems. Greater understanding of the molecular mechanisms underlying the action of these factors will allow the design of predictive algorithms and adequate mobilization protocols in the future [66].

The α4 integrin antibody (CD49d) natalizumab, another proposed agent, achieves adequate cell mobilization in patients with a poor response to G-CSF and plerixafor [66, 125, 126]. Natalizumab is a recombinant humanized IgG4 monoclonal antibody that binds to the α-4 subunit of the α-4-β1 integrin and inhibits the α-4-mediated adhesions of leukocytes to their counterreceptors. It has been used in the treatment of multiple sclerosis (MS) and Crohn's disease. In relapsed MS patients, a single dose (300 mg) of natalizumab produced a 5-fold increase in circulating CD34+ cells one day later [126]. POL 6326, a CXCR4 antagonist, was studied in MM patients and healthy volunteers and proved to be well tolerated and effective in the mobilization of CD34+ cells [127]. Recent results showed that the addition of BKT140 (4F-benzoyl-TN14003), another CXCR4 antagonist, to G-CSF can increase the mobilization of CD34+ cells and reduce the number of aphereses. BKT140 has also shown an antitumor effect, increasing apoptosis in human-derived MM, lymphoma, and primary leukemia cells, although further research is required to establish its anti-MM effects [128].

4.3. Stem Cell Therapy in Ischemic Heart Disease. Over the past few years, interest has grown in the application of stem cell therapy in ischemic heart disease. In myocardial repair, stem cell homing signals play a decisive role in mobilizing BM stem cells towards the ischemic area of the heart. The therapy is designed to enhance the homing, survival, persistence, and differentiation of stem cells in the infarcted area, and the chemokine SDF-1α/CXCL12 has proven to be the most potent stem cell homing factor [129]. Research by Wang and Luther [130] on the infarcted heart showed that hypoxic preconditioning activates SDF-1α/CXCR4 signaling and upregulates vascular/angiogenic factors that mobilize progenitor cells. SDF-1α secretion in the infarcted heart creates an environment that enhances the homing of circulating CXCR4+ stem cells and other stem cells. BM-derived mesenchymal stem cells have shown good results in post-MI cardiac repair [131]. In a study of patients with acute MI, Karapetyan et al. [132] found that the bioactive sphingophospholipids, SPI and CPI, regulate trafficking of HSPCs. Stem cell-based and microRNA (miRNA, miR) based therapeutic strategies appear to offer a promising perspective for patients with cardiovascular disease, especially MI [133].

5. Stem Cell Mobilization in BM and Clinical Trials

Clinical trial NCT00536887 (Effects of atorvastatin 10 mg versus 40 mg in eight-month followup coronary flow reserve and bone marrow stem cell mobilization in patients with acute myocardial infarction) demonstrated that different doses (10–40 mg) of atorvastatin were effective to enhance BM stem cell mobilization in patients with acute MI, increasing the mobilization of CD34+ and CXCR4+ cells, reducing cytokine levels and regenerating microvascular integrity [134]. Although this trial ended in 2008, the final results had not been published at the time of writing this review.

Another clinical trial in acute MI patients (NCT00126100: Bone marrow stem cell mobilization therapy for acute myocardial infarction [REVIVAL-2]), which was completed, reported that transplantation of blood-derived or BM-derived progenitor cells can improve cardiac regeneration and that G-CSF induces BM stem cell mobilization and increases the number of circulating stem cells available for this purpose [135, 136].
The Gregorio Marañón Hospital in Spain is running a Phase 2 clinical trial (NCT00984178: Trial of hematopoietic stem cells in acute myocardial infarction [TECAM2]) to compare the effectiveness of four strategies to prevent postinfarction ventricular remodeling: conventional treatment for reperfused extensive acute myocardial infarction; intracoronary transplantation of autologous bone marrow stem cells; mobilization of bone marrow stem-cells induced by G-CSF; and the combination of stem-cell transplantation with G-CSF-induced mobilization. This trial is currently recruiting participants, and no date has yet been given for the end of the study.

Clinical trial NCT00001071 (A study of stem cells and filgrastims) was carried out in patients at various stages of HIV-1 infection and in HIV-negative volunteers and investigated the safety of stem cell harvesting after using filgrastim (G-CSF) to mobilize BM stem cells into the peripheral blood. This study, which has ended, found that the mobilization and harvesting of bone marrow progenitor cells from persons infected with HIV-1 induced a transient increase in viral replication in some patients but was not associated with adverse effects [137, 138].

Clinical trial NCT00011830 (Stem cell mobilization potential in patients with aplastic anemia in remission) studied the use of filgrastim in patients with aplastic anemia (aged ≥12 years) in remission after successful treatment with immunosuppressive drugs.

It investigated whether G-CSF administration generates sufficient BM-produced cells that mature into white/red blood cells and platelets for use in future treatments and whether successfully treated patients who then relapse can benefit from autologous stem cell transfusion. G-CSF was s.c. injected daily for up to 10 days. Stem cells were collected by apheresis, usually after 5 or 6 days of filgrastim injections. The results of this trial have not yet been published.

6. Conclusions

HSPCs are mobilized from the BM in various situations, including hematopoietic transplantation, AMI, bone marrow injuries, and stroke, among others. Researchers have demonstrated that regulation of the mobilization and homing of HPCs from the BM plays a critical role in repairing damage to different tissues. Various factors influence the regulation mechanisms for HSPC mobilization and homing from the BM, including SDF-1 and its CXCR4, which have been implicated as a major pathway for regulating the migration and mobilization of HSPCs under steady-state conditions. G-CSF induces HSPC mobilization through the proteolytic inactivation of CXCL12 and CXCR4 by NE and CG and through the interaction of other ligands such as VLA-4 and VCAM-1 in BM stromal cells. It is now possible to accurately quantify the mobilization of stem cells by direct measurement in the BM, allowing comparison of the efficacy of different agents over the short and long term. Mobilizing agents being used in different diseases include the distinct forms of G-CSF and, especially, plerixafor, which has represented a major advance in novel strategies for HSPCs mobilization, especially in patients with a history of mobilization failure. Various clinical trials are under way to evaluate the effectiveness of different factors for the mobilization of BM stem cells.

Authors’ Contribution

P. Alvarez and E. Carrillo contributed equally to this work.

References

[1] A. Gratwohl, H. Baldomero, O. Schmid et al., “Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003,” Bone Marrow Transplantation, vol. 36, no. 7, pp. 575–590, 2005.
[2] S. Massberg and U. H. Von Andrian, “Novel trafficking routes for hematopoietic stem and progenitor cells,” Annals of the New York Academy of Sciences, vol. 1176, pp. 87–93, 2009.
[3] A. Spradling, D. Drummond-Barbosa, and T. Kai, “Stem cells find their niche,” Nature, vol. 414, no. 6859, pp. 98–104, 2001.
[4] H. G. Kopp, S. T. Avecella, A. T. Hooper, and S. Rafii, “The bone marrow vascular niche: home of HSC differentiation and mobilization,” Physiology, vol. 20, no. 5, pp. 349–356, 2004.
[5] T. Lapidot, A. Dar, and O. Kollet, “How do stem cells find their way home?” Blood, vol. 106, no. 6, pp. 1901–1910, 2005.
[6] H. Baldomero, M. Gratwohl, A. Gratwohl et al., “The EBMT activity survey 2009: trends over the past 5 years,” Bone Marrow Transplantation, vol. 46, no. 4, pp. 485–501, 2011.
[7] A. Gratwohl and H. Baldomero, “Trends of hematopoietic stem cell transplantation in the third millennium,” Current Opinion in Hematology, vol. 16, no. 6, pp. 420–426, 2009.
[8] Y. Cohen and A. Nagler, “Umbilical cord blood transplantation—how, when and for whom?” Blood Reviews, vol. 18, no. 3, pp. 167–179, 2004.
[9] S. Couban, D. R. Simpson, M. J. Barnett et al., “A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies,” Blood, vol. 100, no. 5, pp. 1525–1531, 2002.
[10] O. Ringdén, M. Labopin, A. Bacigalupo et al., “Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 20, no. 24, pp. 4655–4664, 2002.
[11] M. Z. Ratajczak, C. H. Kim, A. Abdel-Latif et al., “A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients,” Leukemia, vol. 26, no. 1, pp. 63–72, 2012.
[12] N. Kränkel, G. Spinetti, S. Amadesic, and P. Madeddu, “Targeting stem cell niches and trafficking for cardiovascular therapy,” Pharmacology Therapeutics, vol. 129, no. 1, pp. 62–81, 2011.
[13] T. B. Campbell, G. Hangoc, Y. Liu, K. Pollok, and H. E. Broxmeyer, “Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice,” Stem Cells and Development, vol. 16, no. 3, pp. 347–353, 2007.
[14] T. Kawai, U. Choi, P.-C. Liu, N. L. Whiting-Theobald, G. F. Linton, and H. L. Malech, “Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly
enhances engraftment of human mobilized CD34+ peripheral blood cells,” Stem Cells and Development, vol. 16, no. 3, pp. 361–370, 2007.

[15] A. Haghighat, D. Weiss, M. K. Whalin, D. P. Cowan, and W. R. Taylor, “Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice,” Circulation, vol. 115, no. 15, pp. 2049–2054, 2007.

[16] O. Tura, J. Crawford, G. R. Barclay et al., “Granulocyte colony-stimulating factor mutant in H9c2 rat cardiomyocytes,” Journal of Thrombosis and Haemostasis, vol. 8, no. 7, pp. 1614–1623, 2010.

[17] H. K. Chung, E. M. Ko, S. W. Kim et al., “Antipapoptotic effects of Phe140Asn, a novel human granulocyte colony-stimulating factor mutant in H9c2 rat cardiomyocytes,” Biochemistry and Molecular Biology Reports, vol. 458, no. 127, pp. 742–747, 2012.

[18] Z. H. Fu, W. Dong, L. Y. Gai, F. Wang, R. Ding, and Y. D. Chen, “Effect of erythropoietin combined with granulocyte-colony stimulating factor in the treatment of acute myocardial infarction in rats,” Journal of Southern Medical University, vol. 31, no. 1, pp. 17–22, 2011.

[19] Y. Guo, C. Liu, and J. He, “Effect of combined therapy of granulocyte colony stimulating factor and bone marrow mesenchymal stem cells carrying hepatocyte growth factor gene on angiogenesis of myocardial infarction in rats,” Chinese Journal of Reparative and Reconstructive Surgery, vol. 25, no. 6, pp. 736–740, 2011.

[20] L. M. Pelus, H. Bian, S. Fukuda, D. Wong, A. Merzouk, and H. Saliari, “The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor,” Experimental Hematology, vol. 33, no. 3, pp. 295–307, 2005.

[21] T. Sugiyama, H. Kohara, M. Noda, and T. Nagasawa, “Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches,” Immunity, vol. 25, no. 6, pp. 977–988, 2006.

[22] S. Méndez-Ferrer, D. Lucas, M. Battista, and P. S. Frenette, “Haematopoietic stem cell release is regulated by circadian oscillations,” Nature, vol. 452, no. 7186, pp. 442–447, 2008.

[23] K. Balabanian, B. Lagane, S. Infantino et al., “The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes,” Journal of Biological Chemistry, vol. 280, no. 42, pp. 35760–35766, 2005.

[24] M. Qing, D. Jones, and T. A. Springer, “The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment,” Immunity, vol. 10, no. 4, pp. 463–471, 1999.

[25] S. M. Rankin, “Chemokines and adult bone marrow stem cells,” Immunology Letters, vol. 145, pp. 147–254, 2012.

[26] L. E. Perez, O. Alpdogan, J.-H. Shiieh et al., “Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice,” Experimental Hematology, vol. 32, no. 3, pp. 300–307, 2004.

[27] N. Flomenberg, S. M. Devine, J. F. DiPersio et al., “The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone,” Blood, vol. 106, no. 5, pp. 1867–1874, 2005.

[28] T. Gangadhar, S. Nandi, and R. Salgia, “The role of chemokine receptor CXCR4 in lung cancer,” Cancer Biology and Therapy, vol. 9, no. 6, pp. 409–416, 2010.

[29] B. A. Zabel, S. Lewén, R. D. Berahovich, J. C. Jaén, and T. J. Schall, “The novel chemokine receptor CXCR7 regulates transendothelial migration of cancer cells,” Molecular Cancer, vol. 10, article no. 73, 2011.

[30] W. C. Liles, H. E. Broxmeyer, E. Rodger et al., “Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist,” Blood, vol. 102, no. 8, pp. 2728–2730, 2003.

[31] J. Wang, Y. Shiozawa, J. Wang et al., “The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer,” Journal of Biological Chemistry, vol. 283, no. 7, pp. 4283–4294, 2008.

[32] E. Schutyser, Y. Su, Y. Yu et al., “Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells,” European Cytokine Network, vol. 18, no. 2, pp. 59–70, 2007.

[33] A. Dar, O. Kollet, and T. Lapidot, “Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice,” Experimental Hematology, vol. 34, no. 8, pp. 967–975, 2006.

[34] Y. Vagima, K. Lapid, O. Kollet, P. Goichberg, R. Alon, and T. Lapidot, “Pathways implicated in stem cell migration: the SDF-1/CXCR4 axis,” Methods in Molecular Biology, vol. 750, pp. 277–289, 2011.

[35] K. Hattori, B. Heissig, K. Tashiro et al., “Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells,” Blood, vol. 97, no. 11, pp. 3354–3360, 2001.

[36] D. H. Walter, U. Rochwalsky, J. Reinhold et al., “Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the SIP3 receptor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 275–282, 2007.

[37] C. H. Kim, W. Wu, M. Wysocki et al., “Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors,” Leukemia, vol. 26, no. 1, pp. 106–116, 2012.

[38] H. M. Lee, W. Wu, M. Wysocki et al., “Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes,” Leukemia, vol. 23, no. 11, pp. 2052–2062, 2009.

[39] A. Avigdor, P. Goichberg, S. Shivtiel et al., “CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow,” Blood, vol. 103, no. 8, pp. 2981–2989, 2004.

[40] B. Heissig, K. Hattori, S. Dias et al., “Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand,” Cell, vol. 109, no. 5, pp. 625–637, 2002.

[41] J. G. Winkler and J.-P. Lévesque, “Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone,” Experimental Hematology, vol. 34, no. 8, pp. 996–1009, 2006.

[42] J.-P. Lévesque, J. Hendy, Y. Takamatsu, B. Williams, I. G. Winkler, and P. J. Simmons, “Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms
the bone marrow into a highly proteolytic environment,” *Experimental Hematology*, vol. 30, no. 5, pp. 440–449, 2002.

[43] F. J. Castellino and V. A. Ploplis, “Structure and function of the plasminogen/plasmin system,” *Thrombosis and Haemostasis*, vol. 93, no. 4, pp. 647–654, 2005.

[44] Y. Gong and J. Hoover-Plow, “The plasminogen system regulating stem cell mobilization,” *Journal of Biomedicine and Biotechnology*, vol. 2012, Article ID 437920, 7 pages, 2012.

[45] N. Montuori, M. V. Carriero, S. Salzano, G. Rossi, and P. Ragni, “The cleavage of the urokinase receptor regulates its multiple functions,” *Journal of Biological Chemistry*, vol. 277, no. 49, pp. 46932–46939, 2002.

[46] Y. Gazitt, “Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies,” *Leukemia*, vol. 18, no. 1, pp. 1–10, 2004.

[47] C. F. Craddock, B. Nakamoto, R. G. Andrews, G. V. Priestley, and T. Papayannopoulou, “Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice,” *Blood*, vol. 90, no. 12, pp. 4779–4788, 1997.

[48] A. Chigaev, S. S. Winter, and L. A. Sklar, “Is prolonged induced mobilization in primates and mice,” *Antibodies to VLA4 integrin*, 2012.

[49] H. E. Bonig, G. V. Priestley, V. Oehler, and T. Papayannopoulou, “Hematopoietic Progenitor Cells (HPC) from Mobilized Peripheral Blood Display Enhanced Migration and Marrow Homing Compared to Steady-State Bone Marrow HPC,” *Experimental Hematology*, vol. 35, no. 2, pp. 326–334, 2007.

[50] D. E. Wright, A. J. Wagars, A. Pathak Gulati, F. L. Johnson, and I. L. Weissman, “Physiological migration of hematopoietic stem and progenitor cells,” *Science*, vol. 294, no. 5548, pp. 1933–1936, 2001.

[51] H. E. Broxmeyer, C. M. Orschell, D. W. Clapp et al., “Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist,” *Journal of Experimental Medicine*, vol. 201, no. 8, pp. 1307–1318, 2005.

[52] C. Heeschen, A. Aicher, R. Lehmann et al., “Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization,” *Blood*, vol. 102, no. 4, pp. 1340–1346, 2003.

[53] J. Han, Y. J. Koh, H. R. Moon et al., “Adipose tissue is an extramedullary reservoir for functional hematopoietic stem and progenitor cells,” *Blood*, vol. 115, no. 5, pp. 957–964, 2010.

[54] S. C. Pitchford, M. J. Hahnel, C. P. Jones, and S. M. Rankin, “Troubleshooting: quantification of mobilization of progenitor cell subsets from bone marrow in vivo,” *Journal of Pharmacological and Toxicological Methods*, vol. 61, no. 2, pp. 113–121, 2010.

[55] A. F. Cashen, D. Link, S. Devine, and J. DiPersio, “Cytokines and stem cell mobilization for autologous and allogeneic transplantation,” *Current hematology reports*, vol. 3, no. 6, pp. 406–412, 2004.

[56] R. A. Brown, D. Adkins, L. T. Goodnough et al., “Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies,” *Journal of Clinical Oncology*, vol. 15, no. 9, pp. 3067–3074, 1997.

[57] S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella, “Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy,” *Journal of Clinical Oncology*, vol. 18, no. 6, pp. 1360–1377, 2000.

[58] A. M. Greenbaum and D. C. Link, “Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization,” *Leukemia*, vol. 25, no. 2, pp. 211–217, 2011.

[59] C. Cencioni, M. C. Capogrossi, and M. Napolitano, “The SDF-1/CXCR4 axis in stem cell preconditioning,” *Cardiovascular Research*, vol. 94, no. 3, pp. 400–407, 2012.

[60] U. Duhrsen, J. L. Villeval, J. Boyd, G. Kannourakis, G. Morstyn, and D. Metcalf, “Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients,” *Blood*, vol. 72, no. 6, pp. 2074–2081, 1988.

[61] F. Lefrère, M. Bernard, F. Audat et al., “Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients,” *Leukemia and Lymphoma*, vol. 35, no. 5–6, pp. 501–505, 1999.

[62] J. C. Fischer, M. Frick, R. Wassmuth, A. Platz, M. Punzel, and P. Wernet, “Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors,” *British Journal of Haematology*, vol. 130, no. 5, pp. 740–746, 2005.

[63] L. B. To, J.-P. Levesque, and K. E. Herbert, “How I treat patients who mobilize hematopoietic stem cells poorly,” *Blood*, vol. 118, no. 17, pp. 4530–4540, 2011.

[64] I. H. Motabi and J. F. DiPersio, “Advances in stem cell mobilization,” *Blood Reviews*, vol. 26, no. 6, pp. 267–278, 2012.

[65] S. Fruehauf, K. Schmitt, M. R. Veldwijk et al., “Periph- eral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients,” *British Journal of Haematology*, vol. 105, no. 3, pp. 786–794, 1999.

[66] M. Mohty and A. D. Ho, “In and out of the niche: perspectives in mobilization of hematopoietic stem cells,” *Experimental Hematology*, vol. 39, no. 7, pp. 723–729, 2011.

[67] W. Ensinger, E. Appelbaum, S. Rowley et al., “Factors that influence collection and engraftment of autologous peripheral-blood stem cells,” *Journal of Clinical Oncology*, vol. 13, no. 10, pp. 2547–2555, 1995.

[68] M. A. Gertz, R. C. Wolf, I. N. Micallef, and D. A. Gastineau, “Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma,” *Blood Marrow Transplantation*, vol. 45, no. 9, pp. 1396–1403, 2010.

[69] R. T. Maziarz, A. P. Nademanee, I. N. Micallef et al., “Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with...
non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells,” *Biology of Blood and Marrow Transplantation*, vol. 19, no. 4, pp. 670–675, 2013.

[23] S. Hashimoto, M. Itoh, M. Nishimura, and T. Asai, “Effect of filgrastim administration for steady-state mobilization of peripheral blood stem cells,” *Therapeutic Apheresis*, vol. 6, no. 6, pp. 431–436, 2002.

[24] N. Kröger, H. Renges, W. Krüger et al., “A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation,” *British Journal of Haematology*, vol. 113, no. 3, pp. 761–765, 2000.

[25] S. J. Ings, C. Balsa, D. Leverett, S. Mackinnon, D. C. Linch, and M. J. Watts, “Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used,” *British Journal of Haematology*, vol. 134, no. 5, pp. 517–525, 2006.

[26] P. S. Becker, M. Wagle, S. Matous et al., “Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells,” *Biology of Blood and Marrow Transplantation*, vol. 3, no. 1, pp. 45–49, 1997.

[27] A. P. Dincer, J. Gottschall, and D. A. Margolis, “Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization,” *Journal of Pediatric Hematology/Oncology*, vol. 26, no. 11, pp. 763–764, 2003.

[28] M. Z. Ratajczak, H. Lee, M. Wysockzny et al., “Novel insight into stem cell mobilization-Plasma sphingosine-1-phosphate is a major chemottractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex,” *Leukemia*, vol. 24, no. 5, pp. 976–985, 2010.

[29] W. P. Sheridan, C. G. Begley, C. A. Juttner et al., “Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy,” *Lancet*, vol. 339, no. 8794, pp. 640–644, 1992.

[30] L. S. Schwartzberg, R. Birch, B. Hazelo et al., “Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor,” *Journal of hematology*, vol. 1, no. 4, pp. 317–327, 1992.

[31] C. Dazzi, A. Cariello, G. Rosti et al., “Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin’s lymphoma?” *Leukemia and Lymphoma*, vol. 39, no. 3–4, pp. 301–310, 2000.

[32] D. Dingli, G. S. Nowakowski, A. Dispensieri et al., “Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma,” *Clinical Lymphoma and Myeloma*, vol. 6, no. 5, pp. 384–388, 2006.

[33] S. Kim, H.-J. Kim, J. S. Park et al., “Prospective randomized comparative observation of single- vs split-dose lenograsim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin’s lymphoma,” *Annals of Hematology*, vol. 84, no. 11, pp. 742–747, 2005.

[34] C. Hosing, R. M. Saliba, S. Ahlawat et al., “Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma,” *American Journal of Hematology*, vol. 84, no. 6, pp. 335–337, 2009.
[100] H. Suzuya, T. Watanabe, R. Nakagawa et al., "Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors," Vox Sang., vol. 89, no. 4, pp. 229–235, 2005.

[101] A. C. Zubair, R. Grant, W. Wu et al., "Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients," Transfusion, vol. 48, no. 6, pp. 1106–1114, 2008.

[102] G. Molineux, Z. Pojda, I. N. Hampson, B. I. Lord, and T. M. Dexter, "Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor," Blood, vol. 76, no. 10, pp. 2153–2158, 1990.

[103] L. N. Gordan, M. W. Sugrue, J. W. Lynch et al., "Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation," Leukemia and Lymphoma, vol. 44, no. 5, pp. 815–820, 2003.

[104] F. Ferraro, S. Lymeri, S. Méndez-Ferrer et al., "Diabetes impairs hematopoietic stem cell mobilization by altering niche function," Science translational medicine, vol. 3, no. 104, article 104ra101, 2011.

[105] D. Lysák, M. Hrabětová, J. Vrzalová et al., "Changes of cytokine levels during granulocyte-colony-stimulating factor stem cell mobilization in healthy donors: association with mobilization efficiency and potential predictive significance," Transfusion, vol. 51, no. 2, pp. 319–327, 2011.

[106] A. F. Cashen, B. Nervi, and J. DiPersio, "AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent," Future Oncology, vol. 3, no. 1, pp. 19–27, 2007.

[107] S. M. Devine, N. Flomenberg, D. H. Vesole et al., "Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma," Journal of Clinical Oncology, vol. 22, no. 6, pp. 1095–1102, 2004.

[108] R. F. Duarte, B. E. Shaw, P. Marín et al., "Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data," Bone Marrow Transplantation, vol. 46, no. 1, pp. 52–58, 2011.

[109] W. C. Liles, E. Rodger, H. E. Broxmeyer et al., "Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist," Transfusion, vol. 45, no. 3, pp. 295–300, 2005.

[110] K. W. Douglas, A. N. Parker, P. J. Hayden et al., "Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA," Bone Marrow Transplantation, vol. 47, no. 1, pp. 18–23, 2012.

[111] S. Abhyankar, S. Dejarnette, O. Aljitiwà, S. Ganguly, D. Merkel, and J. McGuirk, "A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor," Bone Marrow Transplantation, vol. 47, no. 4, pp. 483–487, 2012.

[112] M. R. Kessans, M. L. Gatesman, and D. R. Kockler, "Plerixafor: a peripheral blood stem cell mobilizer," Pharmacotherapy, vol. 30, no. 5, pp. 485–492, 2010.

[113] E. Jantunen, "Novel strategies for blood stem cell mobilization: special focus on plerixafor," Expert Opinion on Biological Therapy, vol. 11, no. 9, pp. 1241–1248, 2011.

[114] A. Cashen, S. Lopez, F. Gao et al., "A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma," Biology of Blood and Marrow Transplantation, vol. 14, no. 11, pp. 1253–1261, 2008.

[115] G. Calandra, J. McCarty, J. McGuirk et al., "AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data," Bone Marrow Transplantation, vol. 41, no. 4, pp. 331–338, 2008.

[116] I. N. Micallef, P. J. Stiff, J. F. DiPersio et al., "Successful stem cell mobilization using plerixafor (Mozobil) plus granulocyte-colony-stimulating factor in patients with non-Hodgkin Lymphoma: results from the plerixafor NHL phase 3 study rescue protocol," Biology of Blood and Marrow Transplantation, vol. 15, no. 12, pp. 1578–1586, 2009.

[117] M. Steinberg and M. Silva, "Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-hodgkin's lymphoma or multiple myeloma," Clinical Therapeutics, vol. 32, no. 5, pp. 821–843, 2010.

[118] P. Stiff, I. Micallef, P. McCarthy et al., "Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient," Biology of Blood and Marrow Transplantation, vol. 15, no. 2, pp. 249–256, 2009.

[119] E. Jantunen and G. Kvalheim, "Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies," European Journal of Haematology, vol. 85, no. 6, pp. 463–471, 2010.

[120] M. J. Dugan, R. T. Mazariz, W. I. Bensinger et al., "Safety and preliminary efficacy of plerixafor (mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization," Bone Marrow Transplantation, vol. 45, no. 1, pp. 39–47, 2010.

[121] E. Yannaki, T. Papayannopoulou, E. Jonlin et al., "Hematopoietic stem cell mobilization for gene therapy of adult patients with severe B-thalassemia results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects," Molecular Therapy, vol. 20, no. 1, pp. 230–238, 2012.

[122] C. Saure, C. Weigelt, T. Schroeder et al., "Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer," Acta Haematologica, vol. 124, no. 4, pp. 235–238, 2010.

[123] S. Sinha, D. Gastineau, I. Micallef et al., "Predicting PBSC harvest failure using circulating CD34 levels: developing targeted-based cutoff points for early intervention," Bone Marrow Transplantation, vol. 46, no. 7, pp. 943–949, 2011.

[124] F. T. Awan, S. T. Kochuparambil, D. Deremer et al., "Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and Filgrastim-based peripheral blood progenitor cell mobilization," Journal of Oncology, vol. 2012, Article ID 931071, 5 pages, 2012.

[125] F. Zohren, D. Toutzaris, V. Klärner, H.-P. Hartung, B. Kiefer, and R. Haas, "The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34 hematopoietic progenitor cells in humans," Blood, vol. 111, no. 7, pp. 3893–3895, 2008.

[126] H. Bonig, A. Wundes, K.-H. Chang, S. Lucas, and T. Papayannopoulou, "Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in..."
patients treated with the CD49d blocking antibody natalizumab,” *Blood*, vol. 111, no. 7, pp. 3439–3441, 2008.

[127] S. Schmitt, N. Weinhold, K. Dembowski et al., “First results of a phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HCS) in multiple myeloma (MM),” *Blood*, vol. 116, abstract 824, no. 21, Proceedings of the ASH Annual Meeting Abstracts, 2010.

[128] A. Nagler, A. Shimoni, I. Avivi et al., “BKT140 is a novel CXCR4 antagonist with stem cell mobilization and antamyeloma effects: an open-label first human trial in patients with multiple myeloma undergoing stem cell mobilization for autologous transplantation,” *Blood*, vol. 116, abstract 2260, no. 21, Proceedings of the ASH Annual Meeting Abstracts, 2010.

[129] S. K. Ghadge, S. Mühlstedt, C. Özcelik, and M. Bader, “SDF-1α as a therapeutic stem cell homing factor in myocardial infarction,” *Pharmacology and Therapeutics*, vol. 129, no. 1, pp. 97–108, 2011.

[130] Y. Wang and K. Luther, “Genetically manipulated progenitor/stem cells restore function to the infarcted heart via the SDF-1α/CXCR4 signaling pathway,” *Progress in Molecular Biology and Translational Science*, vol. 111, pp. 265–284, 2012.

[131] Z. Wen, S. Zheng, C. Zhou, J. Wang, and T. Wang, “Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction,” *Journal of Cellular and Molecular Medicine*, vol. 16, no. 4, pp. 657–671, 2012.

[132] S. J. Hong, S. C. Choi, J. S. Kim et al., “Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-Month effects on coronary flow reserve and angiogenic cell mobilisation,” *Heart*, vol. 96, no. 10, pp. 756–764, 2010.

[133] M. Harada, Y. Qin, H. Takano et al., “G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes,” *Nature Medicine*, vol. 11, no. 3, pp. 305–311, 2005.

[134] D. Zohnhöfer, I. Ott, J. Mehilli et al., “Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial,” *Journal of the American Medical Association*, vol. 295, no. 9, pp. 1003–1010, 2006.

[135] T. B. Campbell, A. Sevin, R. W. Coombs et al., “Changes in human immunodeficiency virus type 1 virus lead during mobilization and harvesting of hemopoietic progenitor cells,” *Blood*, vol. 95, no. 1, pp. 48–55, 2000.

[136] R. T. Schooley, J. Mladenovic, A. Sevin et al., “Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease,” *Journal of Infectious Diseases*, vol. 181, no. 1, pp. 148–157, 2000.
